Talphera Inc. (NASDAQ:TLPH) — Market Cap & Net Worth
Market Cap & Net Worth: Talphera Inc. (TLPH)
Talphera Inc. (NASDAQ:TLPH) has a market capitalization of $41.54 Million ($41.54 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22569 globally and #4731 in its home market, demonstrating a 14.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Talphera Inc.'s stock price $0.92 by its total outstanding shares 46609618 (46.61 Million). Analyse TLPH cash generation efficiency to see how efficiently the company converts income to cash.
Talphera Inc. Market Cap History: 2015 to 2026
Talphera Inc.'s market capitalization history from 2015 to 2026. Data shows change from $3.59 Billion to $42.82 Million (-33.97% CAGR).
Index Memberships
Talphera Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #648 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2158 of 3165 |
Weight: Talphera Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Talphera Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Talphera Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
52.98x
Talphera Inc.'s market cap is 52.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.59 Billion | $19.26 Million | -$24.40 Million | 186.31x | N/A |
| 2016 | $2.42 Billion | $17.36 Million | -$43.16 Million | 139.64x | N/A |
| 2017 | $1.89 Billion | $8.00 Million | -$51.51 Million | 236.69x | N/A |
| 2018 | $2.15 Billion | $2.15 Million | -$47.15 Million | 1001.10x | N/A |
| 2019 | $1.97 Billion | $2.29 Million | -$53.24 Million | 859.29x | N/A |
| 2020 | $1.16 Billion | $5.42 Million | -$40.38 Million | 213.43x | N/A |
| 2021 | $522.03 Million | $378.00K | -$35.10 Million | 1381.03x | N/A |
| 2022 | $105.34 Million | $1.77 Million | $42.52 Million | 59.48x | 2.48x |
| 2023 | $34.49 Million | $651.00K | -$18.40 Million | 52.98x | N/A |
Competitor Companies of TLPH by Market Capitalization
Companies near Talphera Inc. in the global market cap rankings as of May 3, 2026.
Key companies related to Talphera Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Talphera Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Talphera Inc.'s market cap moved from $3.59 Billion to $ 42.82 Million, with a yearly change of -33.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $42.82 Million | -19.42% |
| 2025 | $53.13 Million | +117.14% |
| 2024 | $24.47 Million | -29.05% |
| 2023 | $34.49 Million | -67.26% |
| 2022 | $105.34 Million | -79.82% |
| 2021 | $522.03 Million | -54.84% |
| 2020 | $1.16 Billion | -41.23% |
| 2019 | $1.97 Billion | -8.66% |
| 2018 | $2.15 Billion | +13.79% |
| 2017 | $1.89 Billion | -21.92% |
| 2016 | $2.42 Billion | -32.47% |
| 2015 | $3.59 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Talphera Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.54 Million USD |
| MoneyControl | $41.54 Million USD |
| MarketWatch | $41.54 Million USD |
| marketcap.company | $41.54 Million USD |
| Reuters | $41.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more